nach oben

Langenbeck's Archives of Surgery

Erschienen in:

01.12.2013 | Review Article

Molecular diagnostics of pancreatic cysts

verfasst von: Hanno Matthaei, Georg Feldmann, Philipp Lingohr, Jörg C. Kalff

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Due to an extensive use of modern imaging, incidental pancreatic cysts are increasingly diagnosed these days. Fortunately, comprehensive research over the past years has remarkably improved our pathogenetic and clinical understanding of pancreatic cysts that, as we know, are in majority harmless. However, mucinous cysts including intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, as well as solid pseudopapillary neoplasms harbor relevant potential for developing into a lethal invasive cancer and may therefore require immediate surgical resection or at least close surveillance. In order to allow an optimized clinical management, it is crucial to gather reliable information about entity as well as biologic behavior of every cyst detected. Unfortunately, in the absence of reliable biomarkers and by just applying currently available diagnostic means such as clinical and radiologic criteria or cyst fluid cytology, there is still a risk for incorrect preoperative diagnoses. This may be followed by inappropriate treatment possibly resulting in severe morbidity or even mortality.

Objective

In this review article, we summarize some of the salient recent advances in molecular diagnostics of pancreatic cysts. Herein, we put particular focus on the emerging field of biomarker research in pancreatic cyst fluid based on protein, DNA, and microRNA analyses.

Kimura W, Nagai H, Kuroda A, Muto T, Esaki Y (1995) Analysis of small cystic lesions of the pancreas. Int J Pancreat 18(3):197–206. doi:10.1007/BF02784942

Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH (2008) Prevalence of unsuspected pancreatic cysts on MDCT. Am J Roentgenol 191(3):802–807. doi:10.2214/AJR.07.3340 CrossRef

Lee KS, Sekhar A, Rofsky NM, Pedrosa I (2010) Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 105(9):2079–2084. doi:10.1038/ajg.2010.122 PubMedCrossRef

Spinelli KS, Fromwiller TE, Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA (2004) Cystic pancreatic neoplasms: observe or operate. Ann Surg 239(5):651–657, discussion 657–659PubMedCrossRef

Girometti R, Intini S, Brondani G, Como G, Londero F, Bresadola F, Zuiani C, Bazzocchi M (2011) Incidental pancreatic cysts on 3D turbo spin echo magnetic resonance cholangiopancreatography: prevalence and relation with clinical and imaging features. Abdom Imaging 36(2):196–205. doi:10.1007/s00261-010-9618-4

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117. doi:10.1038/nature09515 PubMedCrossRef

Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD (2004) Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 239(6):788–797, discussion 797–789PubMedCrossRef

Suzuki Y, Atomi Y, Sugiyama M, Isaji S, Inui K, Kimura W, Sunamura M, Furukawa T, Yanagisawa A, Ariyama J, Takada T, Watanabe H, Suda K (2004) Japanese multiinstitutional study of intraductal papillary mucinous t, mucinous cystic t. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28(3):241–246PubMedCrossRef

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579PubMedCrossRef

10.

Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, Choti MA, Schulick RD, Wolfgang CL, Pawlik TM (2012) Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg 214(1):33–45. doi:10.1016/j.jamcollsurg.2011.09.022 PubMedCrossRef

11.

Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL (2003) Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 138(4):427–423. doi:10.1001/archsurg.138.4.427, discussion 433–424PubMedCrossRef

12.

Matthaei H, Schulick RD, Hruban RH, Maitra A (2011) Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 8(3):141–150. doi:10.1038/nrgastro.2011.2 PubMedCrossRef

13.

Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernandez-Del Castillo C (2010) Incidental pancreatic cysts: do we really know what we are watching? Pancreatology 10(2–3):144–150. doi:10.1159/000243733 PubMedCrossRef

14.

Reddy S, Wolfgang CL (2009) Solid pseudopapillary neoplasms of the pancreas. Adv Surg 43:269–282PubMedCrossRef

15.

Khashab MA, Shin EJ, Amateau S, Canto MI, Hruban RH, Fishman EK, Cameron JL, Edil BH, Wolfgang CL, Schulick RD, Giday S (2011) Tumor size and location correlate with behavior of pancreatic serous cystic neoplasms. Am J Gastroenterol 106(8):1521–1526. doi:10.1038/ajg.2011.117 PubMedCrossRef

16.

Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S, International Association of P (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6(1–2):17–32. doi:10.1159/000090023 PubMedCrossRef

17.

Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K, International Association of P (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12(3):183–197. doi:10.1016/j.pan.2012.04.004 PubMedCrossRef

18.

Tang RS, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, Chaudhari V, Raman S, Farrell JJ (2008) Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 6(7):815–819. doi:10.1016/j.cgh.2008.04.005, quiz 719PubMedCrossRef

19.

Pelaez-Luna M, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, Pearson RK, Petersen BT, Topazian MD, Vege SS, Kendrick M, Farnell MB (2007) Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 102(8):1759–1764. doi:10.1111/j.1572-0241.2007.01224.x PubMedCrossRef

20.

Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, Bundy BD, Buchler MW, Werner J (2012) Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 256(2):313–320. doi:10.1097/SLA.0b013e31825d355f PubMedCrossRef

21.

Varadarajulu S, Christein JD, Wilcox CM (2011) Frequency of complications during EUS-guided drainage of pancreatic fluid collections in 148 consecutive patients. J Gastroenterol Hepatol 26(10):1504–1508. doi:10.1111/j.1440-1746.2011.06771.x PubMedCrossRef

22.

Khashab MA, Kim K, Lennon AM, Shin EJ, Tignor AS, Amateau SK, Singh VK, Wolfgang CL, Hruban RH, Canto MI (2013) Should we do EUS/FNA on patients with pancreatic cysts? The incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas 42(4):717–721. doi:10.1097/MPA.0b013e3182883a91 PubMedCrossRef

23.

van der Waaij LA, van Dullemen HM, Porte RJ (2005) Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 62(3):383–389PubMedCrossRef

24.

Levy MJ, Gleeson FC, Campion MB, Caudill JL, Clain JE, Halling K, Rajan E, Topazian MD, Wang KK, Wiersema MJ, Clayton A (2010) Prospective cytological assessment of gastrointestinal luminal fluid acquired during EUS: a potential source of false-positive FNA and needle tract seeding. Am J Gastroenterol 105(6):1311–1318. doi:10.1038/ajg.2010.80 PubMedCrossRef

25.

Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J, Kamel I, Lennon AM, Borges M, Young A, Fujiwara S, Seike J, Eshleman J, Hruban RH, Canto MI, Goggins M (2013) Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62(7):1024–1033. doi:10.1136/gutjnl-2012-302823 PubMedCrossRef

26.

Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, Lee J, Kamel I, Lennon AM, Knight S, Fujiwara S, Hruban RH, Canto MI, Goggins M (2013) Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 11(6):719–730. doi:10.1016/j.cgh.2012.11.016, e715PubMedCrossRef

27.

Yu HC, Shetty J (1985) Mucinous cystic neoplasm of the pancreas with high carcinoembryonic antigen. Arch Pathol Lab Med 109(4):375–377PubMed

28.

Pinto MM, Kaye AD, Brogan DA, Criscuolo EH (1986) Diagnosis of cystic lesions of the pancreas: a biochemical and cytologic analysis of material obtained utilizing radiographic or intraoperative technique. Diag Cytopathol 2(1):40–45CrossRef

29.

Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL (2004) Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 126(5):1330–1336PubMedCrossRef

30.

Ngamruengphong S, Bartel MJ, Raimondo M (2013) Cyst carcinoembryonic antigen in differentiating pancreatic cysts: A meta-analysis. Digest Liver Dis. doi:10.1016/j.dld.2013.05.002

31.

Allen PJ, Qin LX, Tang L, Klimstra D, Brennan MF, Lokshin A (2009) Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg 250(5):754–760. doi:10.1097/SLA.0b013e3181bd7f20 PubMedCrossRef

32.

Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, Jarnagin WR, Allen PJ (2011) Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 17(6):1502–1508. doi:10.1158/1078-0432.CCR-10-1561 PubMedCrossRef

33.

Li C, Simeone DM, Brenner DE, Anderson MA, Shedden KA, Ruffin MT, Lubman DM (2009) Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J Proteome Res 8(2):483–492. doi:10.1021/pr8007013 PubMedCrossRef

34.

Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, Schmidt CM, Feng Z, Simeone DM (2010) Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg 251(5):937–945. doi:10.1097/SLA.0b013e3181d7738d PubMedCrossRef

35.

Cao Z, Maupin K, Curnutte B, Fallon B, Feasley CL, Brouhard E, Kwon R, West CM, Cunningham J, Brand R, Castelli P, Crippa S, Feng Z, Allen P, Simeone DM, Haab BB (2013) Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from non-mucinous pancreatic cysts. Mol Cell Proteomics. doi:10.1074/mcp.M113.030700

36.

Bausch D, Mino-Kenudson M, Fernández-Del Castillo C, Warshaw AL, Kelly KA, Thayer SP (2009) Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. J Gastrointest Surg 13(11):1948–1954. doi:10.1007/s11605-009-1001-9

37.

Bausch D, Thomas S, Mino-Kenudson M, Fernández-del CC, Bauer TW, Williams M, Warshaw AL, Thayer SP, Kelly KA (2011) Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 17(2):302–309. doi:10.1158/1078-0432.CCR-10-0999

38.

Khalid A, McGrath KM, Zahid M, Wilson M, Brody D, Swalsky P, Moser AJ, Lee KK, Slivka A, Whitcomb DC, Finkelstein S (2005) The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 3(10):967–973PubMedCrossRef

39.

Schoedel KE, Finkelstein SD, Ohori NP (2006) K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol 34(9):605–608. doi:10.1002/dc.20511 PubMedCrossRef

40.

Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, Brugge WR, Edmundowicz SA, Hawes RH, McGrath KM (2009) Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 69(6):1095–1102. doi:10.1016/j.gie.2008.07.033 PubMedCrossRef

41.

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–1203. doi:10.1126/science.1200609 PubMedCrossRef

42.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710 PubMedCrossRef

43.

Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108(52):21188–21193. doi:10.1073/pnas.1118046108 PubMedCrossRef

44.

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806. doi:10.1126/science.1164368 PubMedCrossRef

45.

Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340(6236):692–696. doi:10.1038/340692a0 PubMedCrossRef

46.

Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, Kleinman G, Wang Y, Bruce JN, Post KD (2007) Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 10(3):275–282. doi:10.1007/s11102-007-0058-2 PubMedCrossRef

47.

Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325(24):1688–1695. doi:10.1056/NEJM199112123252403 PubMedCrossRef

48.

Lumbroso S, Paris F, Sultan C (2004) Activating Gsa Mutations: Analysis of 113 Patients with Signs of McCune-Albright Syndrome–A European Collaborative Study. J Clin Endocrinol Metab 89(5):2107–2113. doi:10.1210/jc.2003-031225 PubMedCrossRef

49.

Imanaka M, Iida K, Nishizawa H, Fukuoka H, Takeno R, Takahashi K, Kaji H, Takahashi Y, Okimura Y, Kaji H, Imanishi Y, Chihara K (2007) McCune-Albright Syndrome with Acromegaly and Fibrous Dysplasia Associated with the GNAS Gene Mutation Identified by Sensitive PNA-clamping Method. Intern Med 46(18):1577–1583PubMedCrossRef

50.

Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B (2011) Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3(92):92ra66. doi:10.1126/scitranslmed.3002543 PubMedCrossRef

51.

Dal Molin M, Matthaei H, Wu J, Blackford A, Debeljak M, Rezaee N, Wolfgang CL, Butturini G, Salvia R, Bassi C, Goggins MG, Kinzler KW, Vogelstein B, Eshleman JR, Hruban RH, Maitra A (2013) Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg Oncol. doi:10.1245/s10434-013-3096-1 PubMed

52.

Furukawa T, Kuboki Y, Tanji E, Yoshida S, Hatori T, Yamamoto M, Shibata N, Shimizu K, Kamatani N, Shiratori K (2011) Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1:161. doi:10.1038/srep00161 PubMedCrossRef

53.

Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, Maitra A, Matthaei H, Eshleman JR, Hruban RH, Kinzler KW, Pandey A, Vogelstein B (2011) Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci USA 108(6):2444–2449. doi:10.1073/pnas.1019203108

54.

Sato N, Fukushima N, Hruban RH, Goggins M (2008) CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 21(3):238–244. doi:10.1038/modpathol.3800991 PubMedCrossRef

55.

Hong SM, Omura N, Vincent A, Li A, Knight S, Yu J, Hruban RH, Goggins M (2012) Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 18(3):700–712. doi:10.1158/1078-0432.CCR-11-1718 PubMedCrossRef

56.

Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854PubMedCrossRef

57.

Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874. doi:10.1038/nrg3074 PubMedCrossRef

58.

Singh PK, Brand RE, Mehla K (2012) MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol 9(6):334–344. doi:10.1038/nrgastro.2012.63 PubMedCrossRef

59.

Woo YM, Park JH (2013) microRNA biomarkers in cystic diseases. BMB Rep 46(7):338–345PubMedCrossRef

60.

Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA (2007) MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30):4442–4452. doi:10.1038/sj.onc.1210228 PubMedCrossRef

61.

Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ Jr, Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, Labourier E, Tsongalis GJ (2008) Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 54(10):1716–1724. doi:10.1373/clinchem.2008.109603 PubMedCrossRef

62.

Ryu JK, Woo SM, Hwang JH, Jeong JB, Yoon YB, Park IA, Han JK, Kim YT (2004) Cyst fluid analysis for the differential diagnosis of pancreatic cysts. Diagn Cytopathol 31(2):100–105. doi:10.1002/dc.20085 PubMedCrossRef

63.

Frampton AE, Gall TM, Giovannetti E, Stebbing J, Castellano L, Jiao LR, Krell J (2013) Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Rev Mol Diagn 13(4):325–329. doi:10.1586/erm.13.18 PubMedCrossRef

64.

Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F, Vandesompele J (2008) High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 36(21):e143. doi:10.1093/nar/gkn725 PubMedCrossRef

Titel: Molecular diagnostics of pancreatic cysts
verfasst von: Hanno Matthaei
Georg Feldmann
Philipp Lingohr
Jörg C. Kalff
Publikationsdatum: 01.12.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Langenbeck's Archives of Surgery / Ausgabe 8/2013
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-013-1116-z

Neu im Fachgebiet Chirurgie

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

10.04.2024 | Narbenhernie | Nachrichten

Deutlich weniger Narbenhernien mit der Small-Bites-Technik

09.04.2024 | Appendektomie | Nachrichten

Appendektomie: Vorsicht bei systemischen Glukokortikoiden!

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Introduction

Objective

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2013

Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor?

Segmental tracheal resection for invasive differentiated thyroid carcinoma. Our experience in eight cases

Surgical strategy for T2 and T3 gallbladder cancer: is extrahepatic bile duct resection always necessary?

ENERgized vessel sealing systems versus CONventional hemostasis techniques in thyroid surgery—the ENERCON systematic review and network meta-analysis

A comparative North American experience of robotic thyroidectomy in a thyroid cancer population

Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation

Neu im Fachgebiet Chirurgie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Deutlich weniger Narbenhernien mit der Small-Bites-Technik

Appendektomie: Vorsicht bei systemischen Glukokortikoiden!

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“